Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Research Article

Investigating the Efficacy of HPV Vaccines in Preventing Cervical Cancer from 2006 to 2018 in the US: A SEER Data Set Analysis

Author(s): Alexander Mattis*, Hind Beydoun, Yuliya Dobrydneva and Rohini Ganjoo

Volume 18, Issue 3, 2023

Published on: 04 May, 2023

Page: [214 - 222] Pages: 9

DOI: 10.2174/1574887118666230410093715

open access plus

Abstract

Background: Human papillomavirus (HPV) is the most common sexually transmitted infection in the US.The first HPV vaccine was introduced in 2006. There are three different HPV vaccines that commonly target high-risk HPV types.

Objective: This study compares HPV vaccine efficacy based on alternative endpoints with the most recently available cervical cancer incidence data from the Surveillance, Epidemiology and End Results (SEER) program and SEER*Stat statistical software.

Methods: The incidence of cervical cancer, mined from the most recent April 2021 SEER data set, was stratified according to age and racial groups. Trend analysis reporting cervical cancer incidence percentage change (PC) and annual percentage change (APC) was calculated by SEER*Stat statistical software.

Results: A total of 46,583 cases of cervical cancer were reported, with an average of about 3,580 incidents of cervical cancer per year, with an overall decrement of about 60 cases over the period of 12 years. The percentage change according to age and race groups varied between -15.9 among 40- 44 years old (yo) and +13.8 among 30-34 yo, and from -12 among non-Hispanic White women to +13 among Hispanic women. Statistically significant APC was observed for five of the nine age groups and four of the five racial groups.

Conclusion: There seems to be little if any, correlation between cervical cancer incidence and the HPV vaccine program in the US. HPV vaccine efficacy based on alternative endpoints, such as nucleic acid testing and cytological, surgical, and seropositivity endpoints, is fair. Therefore, it is important to emphasize such alternative testing and surrogate endpoints.

Keywords: Human papillomavirus, cervical cancer, vaccine efficacy, cancer incidence, SEER, alternative endpoints, sexually transmitted infection.

Graphical Abstract
[1]
Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: A randomised, double-blind trial. Lancet 2017; 390(10108): 2143-59.
[http://dx.doi.org/10.1016/S0140-6736(17)31821-4] [PMID: 28886907]
[2]
Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J Oncol 2019; 2019: 1-11.
[http://dx.doi.org/10.1155/2019/3257939] [PMID: 31687023]
[3]
Harper DH, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol 2017; 146(1): 196-204.
[http://dx.doi.org/10.1016/j.ygyno.2017.04.004]
[4]
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370(9590): 890-907.
[http://dx.doi.org/10.1016/S0140-6736(07)61416-0] [PMID: 17826171]
[5]
McClung NM, Gargano JW, Bennett NM, et al. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014. Cancer Epidemiol Biomarkers Prev 2019; 28(3): 602-9.
[http://dx.doi.org/10.1158/1055-9965.EPI-18-0885] [PMID: 30792242]
[6]
Centers for Disease Control and Prevention. CDC vaccination recommendations. Available From: https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html
[7]
Curry SJ, Krist AH, Owens DK, et al. Screening for Cervical Cancer. JAMA 2018; 320(7): 674-86.
[http://dx.doi.org/10.1001/jama.2018.10897] [PMID: 30140884]
[8]
The National Institute of Health.. SEER data. Available From: https://seer.cancer.gov/data/
[9]
SEER*Stat Database: Incidence - SEER Research LimitedField Data, 21 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program. 2021. Available From: www.seer.cancer.gov
[10]
The National Institute of Health. SEERStat* WebHelp manual. Available From: https://seer.cancer.gov/seerstat/WebHelp/seerstat.htm (Accessed June 8, 2021).
[11]
Meites E, Gee J, Unger E, Markowitz L. Centers for Disease Control HPV pamphlet. Available From: https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html (Accessed March 19, 2021).
[12]
Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open 2017; 7(8): e015867.
[http://dx.doi.org/10.1136/bmjopen-2017-015867] [PMID: 28821519]
[13]
Talibova N, Sohaib A, Gouda M, Gunaldi M. Incidence and Survival Rates of Gynecological Malignancies in The United States Before and After the HPV Vaccine. Tumori 2020; 106 (Suppl. 1): 22-2.
[http://dx.doi.org/10.1177/0300891620914152]
[14]
Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29(32): 4294-301.
[http://dx.doi.org/10.1200/JCO.2011.36.4596] [PMID: 21969503]
[15]
Centers for Disease Control and Prevention. HPV cancers.. Available From: https://www.cdc.gov/hpv/parents/cancer.html (Accessed September 27, 2021).
[16]
Boersma P, Black LI. Human papillomavirus vaccination among adults aged 18−26, 2013−2018. In: NCHS Data Brief. Hyattsville, MD: National Center for Health Statistics 2020. Available From: https://www.cdc.gov/nchs/data/databriefs/db354-h.pdf
[17]
Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: A systematic quantitative review. Braz J Infect Dis 2014; 18(6): 651-9.
[http://dx.doi.org/10.1016/j.bjid.2014.02.005]
[18]
Karafillakis E, Simas C, Jarrett C, et al. HPV vaccination in a context of public mistrust and uncertainty: A systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother 2019; 15(7-8): 1615-27.
[http://dx.doi.org/10.1080/21645515.2018.1564436] [PMID: 30633623]
[19]
Stephens DP, Tamir H, Thomas TL. Factors Motivating HPV Vaccine Uptake Among Vaccinated and Nonvaccinated Hispanic Young Adult Women. Hisp Health Care Int 2016; 14(4): 184-91.
[http://dx.doi.org/10.1177/1540415316679808] [PMID: 27913692]
[20]
Wheldon CW, Garg A, Galvin AM, Moore JD, Thompson EL. Decision support needs for shared clinical decision-making regarding HPV vaccination among adults 27–45 years of age. Patient Educ Couns 2021; 104(12): 3079-85.
[http://dx.doi.org/10.1016/j.pec.2021.04.016] [PMID: 33980398]
[21]
Cameron RL, Ahmed S, Pollock KGJ. Adverse event monitoring of the human papillomavirus vaccines in Scotland. Intern Med J 2016; 46(4): 452-7.
[http://dx.doi.org/10.1111/imj.13005] [PMID: 26765074]
[22]
Zi W, Yang Q, Su J, He Y, Xie J. OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines. Heliyon 2022; 8(11): e11515.
[http://dx.doi.org/10.1016/j.heliyon.2022.e11515]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy